6 July 2021 (Tuesday) - D-Dimer Assays

The Fritsma Factor newsletter appeared in my on-box this morning. There was quite a bit of note in this instalment including a rather interesting monograph on the D-dimer assay. I’ll quote one bit if I may: “The D-dimer may be elevated in association with a chronic autoimmune condition such as hypothyroidism, rheumatoid arthritis, lupus erythematosus, or diabetes mellitus. D-dimer elevationalso accompanies sarcoidosis, an upper respiratory infection, a systemic infection, recovery from an injury, recovery from surgery, chronic heart disease, or even lifestyle circumstances such as chronic smoking, obesity, psychosocial stress, and exposure to heat, cold, or physical exertion.

You *really* can’t take the numbers that the lab generates in isolation…

4 July 2021 (Sunday) - The Future

I read a post on the Facebook Medical Laboratory Professionals group this morning.

Do you think your job as you know it will exist until you retire?
Well… Quite frankly as long as it sees me out, I’m all right. 
 

Admittedly the question was asked from an American point of view, but from the UK perspective I think it will see me out… but not for those following me.

Blood tests will still be done in the future… but what does a manager do when they advertise a job and get no applicants whatsoever? (when I was a lab manager this was a regular occurrence)

Why no applicants? Look at the trainee positions for which there were no applicants – back in the day you became a trainee from school aged seventeen and your training (up to MSc level) was paid for - it was part of your wages. Nowadays trainees take up post in their mid to late twenties (having paid for their own university education) at wages far below what their mates in other lines of work get at that age.
And look at the hours - You will be expected to be available for shifts at any time day and night. I haven’t a complete weekend off in the last month at all, I missed my daughter’s first eight birthday parties and can’t remember when I last had a complete Christmas break.

And do you want to make a career of it? Opportunities for advancement are few and far between, and the pay differential between the pay bands isn’t worth the extra hassle.

How did labs cope with no application for trainee positions? A massive growth in the unqualified lab assistant grades staffed by people with little formal training doing more and more stuff,
And look at cytology screening right now. To deal with staff shortages pretty much all of the south-east’s cytology work has recently been centralised at one huge lab site leaving people with either hundreds of miles to travel to work, or with no work. However it was rather silly to centralise where house prices are sky-high, wasn’t it?

Centralisation and de-skilling await which can only be a bad thing. Take yesterday for example. I had a phone call… a patient was on a heparin-type anticoagulant. The APTT was over the top of the range. Should the doctor increase or decrease the dose? In years to come the labs will be filled with those who don’t know the answer to that question.

Also bear in mind that if you make a mistake (and who doesn’t!) your mistake may well have the potential to kill someone. And when (not if) you make a mistake will anyone remember all the effort that you put in over the years? You may well find yourself dumped and made unemployable by managers desperate to cover their own backs.

I will also make the observation that my son drives a fork-lift truck about and he earns far more than I do. A train driver (with twelve weeks training) earns more than my supervisors get.
There are those who idealistically say they are doing it for the interest or the altruism of the job, but that soon wears off. Like all jobs it can easily get boring and repetitive. Don’t get me wrong – I don’t dislike what I do, and writing this blog goes a long way to keeping me interested, but after forty years doing blood tests I want to sell ice creams or dig graves or do *anything* which is different.
 

Much as I have learned a *lot* in my forty years of testing blood if I had my time again I would do something else.

2 July 2021 (Friday) - ASH Update


The nice people at the American Society of Hematology touched on a few items about haemostatsis in their most recent update. I’ve often mentioned that  struggle to find good CPD in that area…

Here are the highlights in clotting disorders:
Extended Thromboprophylaxis Does Not Reduce VTE Incidence in Hospitalized Patients With Cancer
Extended thromboprophylaxis with enoxaparin, betrixaban, or rivaroxaban does not reduce the risk of VTE events, but may increase the risk of bleeding, in these patients.
Edoxaban Likely Prevents VTE Recurrence in Patients With Lung Cancer, Despite High Rates of Bleeding
The use of edoxaban in patients with lung cancer helped prevent VTE recurrence over six months, but the therapy was associated with bleeding events and did not seem to improve survival substantially, according to research presented at the 2021 ASCO Annual Meeting.
Rivaroxaban Reduces Risk of Cardiovascular Events in Patients With Atrial Fibrillation on Hemodialysis
A low dose of rivaroxaban decreased fatal and nonfatal cardiovascular events and major bleeding complications in these patients, compared with vitamin K antagonists.

29 June 2021 (Tuesday) - Electronic Issue Training

 


I had a little session with one of the seniors today going over the fundamentals of electronic issue this morning with a view to its implementation in a month's time. It all seemed rather straightforward but then, doesn't everything in the training environment. How well it works at 3am when I am on my own and tearing out my few remaining hairs remains to be seem.

28 June 2021 (Monday) - Leukaemia ?


The nice people at Lablogatory sent a case study today. You can read it by clicking here. Back in the day we would have described it as aleukaemic leukaemia.

It is one of those cases of acute leukaemia in which the white cell count *doesn’t* go through the roof. Something to bear in mind when you see iffy looking cells. Just because the white cell count isn’t ten times what you might expect doesn’t mean it isn’t leukaemia..


28 June 2021 (Monday) - e-learning Updates

I did some e-learning today. I started with a refresher on the use of anti-D in the midwifery setting. A refresher is always good… and then I did a refresher on GMP… 

Perhaps I wasn't in the best of frames of mind when I did this... Don't get me wrong - I fully understand the need for audit and documentation and control of what goes on in labs. However is it necessary to labour the point in such pedantic and petty detail? Does an encyclopaedic knowledge and recall of which regulatory body does what actually improve what goes on in the labs?

I think the relevance of the stuff is summed up when I say that I really don’t know what the acronym GMP stands for.

More and more I'm coming to the conclusion that it will very soon be time for me to retire...

25 June 2021 (Friday) - Myeloma


The nice people at the American Society of Hematology sent their update today. Focussing on myeloma it was rather clinical in outlook, but it is all useful stuff…

Here are the highlights in multiple myeloma:
Does Rheumatic Disease Increase Risk of MGUS Progression to Hematologic Malignancies?
Patients with MGUS and concomitant non-antibody–mediated inflammatory rheumatic diseases are at increased risk of progression to overt multiple myeloma, compared with patients who have MGUS without associated rheumatic diseases.
Older Patients With Myeloma May Have Suboptimal Response to COVID-19 Vaccination
These patients experienced reduced efficacy with Pfizer/BioNTech’s COVID-19 vaccine. However, certain factors identified patients who had a higher probability of immune response to vaccination, such as normalized immunoglobulins.
Idecabtagene Ciloleucel Induces Deep Responses in Relapsed/Refractory Multiple Myeloma
Treatment with idecabtagene ciloleucel showed encouraging efficacy in patients with heavily pretreated relapsed and/or refractory multiple myeloma, according to results from the phase II KarMMa study.